A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer.
about
Effects of STI571 (gleevec) on pancreatic cancer cell growthInfluences of the lysosomal associated membrane proteins (Lamp-1, Lamp-2) and Mac-2 binding protein (Mac-2-BP) on the prognosis of pancreatic carcinomaTargeting of suicide gene delivery in pancreatic cancer cells via FGF receptors.Growth factors and their receptors in pancreatic cancer.bax, but not bcl-2, influences the prognosis of human pancreatic cancerCytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer.Prognostic value of PDL1 expression in pancreatic cancerCadherin-11 Is a Cell Surface Marker Up-Regulated in Activated Pancreatic Stellate Cells and Is Involved in Pancreatic Cancer Cell Migration.ARID1B, a member of the human SWI/SNF chromatin remodeling complex, exhibits tumour-suppressor activities in pancreatic cancer cell lines.Genome profiling of pancreatic adenocarcinoma.Aberrant gata-3 expression in human pancreatic cancer.Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer.Bcl-x(L) antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine.Complications of pancreatic surgery.Direct gene transfer into the rat pancreas using DNA-liposomes.
P2860
Q24802841-8673618A-9021-44FC-A31D-D12C6B928540Q28216866-C2251507-E205-40EB-814F-AFDF3B68C6ECQ31063007-B3328E22-637B-4CAD-B6AC-4D5BBAD81C82Q34116893-0C74D615-A650-489A-A94E-1D8C1C253D07Q35352240-0B0187A0-579F-4685-ACF9-CC01DB6EAFBAQ36827083-819BD458-EF29-4F44-B18C-7CEEF1C355AAQ37687595-BBA777A6-1E38-42E8-9E50-768E8183DDB5Q38290146-65F97596-23DF-4453-A310-58FA04EA926FQ39154063-B3FF43E7-0168-4245-AFEB-1F34FDE894C7Q39574924-768975A0-6A93-49B6-A11A-65EC74B87C7AQ40387222-ABA7FC09-8A79-4DFF-B16A-E2DFE4948985Q40636933-6618EB79-1B50-4FA7-9778-32978944DFECQ40680294-5994EC24-8579-406D-AC78-2D219A03E9FDQ42015947-14EABA6A-D4A7-47CE-A665-69C31A6CAB8BQ45886814-B0A1EA3A-0C92-4DB8-9B3C-90D759A88B53
P2860
A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh
1991年學術文章
@zh-hant
name
A randomized controlled trial ...... resectable pancreatic cancer.
@en
A randomized controlled trial of adjuvant immunotherapy
@nl
type
label
A randomized controlled trial ...... resectable pancreatic cancer.
@en
A randomized controlled trial of adjuvant immunotherapy
@nl
prefLabel
A randomized controlled trial ...... resectable pancreatic cancer.
@en
A randomized controlled trial of adjuvant immunotherapy
@nl
P2093
P1433
P1476
A randomized controlled trial ...... resectable pancreatic cancer.
@en
P2093
Gebhardt C
Schultheiss KH
Winkelmann M
P304
P356
10.1002/1097-0142(19911001)68:7<1507::AID-CNCR2820680707>3.0.CO;2-0
P407
P577
1991-10-01T00:00:00Z